The abstract is read at the publisher; the summary is JClub's.
Protein therapeutic binders can be conditionally activated using masking moieties that prevent target binding until release by disease-linked stimuli like altered protease levels or pH.
- Why it matters: Off-site toxicities arise when binders attach to healthy tissue that expresses the same target, so masking is needed to restrict activity to diseased sites.
- What they did: The review surveys protein- and peptide-derived masks that inhibit binding via steric hindrance or affinity-based competition, emphasizing stimulus-triggered removal using protease expression and pH changes.
- The result: These strategies enable conditionally activated, disease-targeted therapeutics for cytokines, antibodies, and derivatives, guiding future design approaches for safer targeting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.